A new study presented at the American Society of Clinical Oncology annual meeting in Chicago suggest that short-term androgen deprivation therapy (STADT) in combination with radiotherapy (RT) in men with intermediate-risk prostate cancer is associated with better outcomes compared with dose-escalated radiotherapy alone.